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The spore-forming gut bacteriumClostridium difficile is the leading cause of antibiotic-associated diarrhea
in hospitalized patients. The major virulence factors are two large glucosylating cytotoxins. Hypervirulent
strains (e.g. ribotype 027) with higher morbidity and mortality additionally produce the binary CDT toxin
(Clostridium difficile transferase) that ADP-ribosylates actin and induces microtubule-based cell
protrusions. Nanobodies are robust single domain antibodies derived from camelid heavy chain antibodies.
Here we report the generation of functional nanobodies against the enzymatic CDTa and the heptameric
receptor binding subunit CDTb. The nanobodies were obtained from a variable-domain repertoire library
isolated from llamas immunizedwith recombinant CDTa orCDTb. Five CDTa-specific nanobodies blocked
CDTa-mediated ADP-ribosylation of actin. Three CDTa-specific and two CDTb-specific nanobodies
neutralized the cytotoxicity of CDTa1b. These nanobodies hold promise as new tools for research,
diagnosis and therapy of C. difficile associated disease.
C
lostridium difficile is a Gram-positive gut bacterium that provokes severe and relapsing diarrhea with
lethality rates of up to 20%1,2.C. difficile is themajor agent of antibiotic-associated colitis3. Disease severity
is determined by the immune status of the patient and by three secretory enzyme toxins that inactivate
host cell proteins by posttranslational modification with ADP-ribose (CDT) or glucose (ToxA, ToxB)4–6. ToxA
and ToxB disrupt the cellular cytoskeleton by glucosylating Rho proteins and are considered the major virulence
factors7,8. Hypervirulent strains, including ribotypes 027 and 078 responsible for outbreaks of severe C. difficile
associated disease (CDAD), additionally produce C. difficile transferase (CDT)3,9–12. CDT is a binary toxin that
ADP-ribosylates actin4,13. This induces formation of long microtubule-based protrusions in epithelial cells that
facilitate adherence of bacteria and increase colonization14,15.
CDT is structurally related to iota toxin and C2 toxins of C. perfringens and C. botulinum4,16. These binary
toxins are composed of a secreted actin-ADP-ribosylating enzymatic subunit (CDTa) and a separately secreted
binding component (CDTb)17. Upon activation by proteolytic cleavage, CDTb binds to lipolysis-stimulated
lipoprotein receptor (LSR), a type 1 membrane protein expressed by gut epithelial cells18. Akin to anthrax lethal
toxin, CDTb is thought to form heptamers that interact with the enzymatic subunit to form a larger toxin
complex18. Following endocytosis of the toxin complex, the low pH of the endosomal compartment induces a
conformational shift of the binding component, which inserts into the membrane and forms a pore allowing
translocation of the enzymatic component to the cell cytosol. Here CDTa ADP-ribosylates actin at Arg177,
causing disruption of the actin cytoskeleton and formation of microtubule-based protrusions13,14. It has been
proposed that CDTa increases pathogenicity ofC. difficile by enhancing bacterial adherence to enteric epithelium
and colonization of the distal gastrointestinal tract13,14. A landmark clinical trial recently showed clinical benefit of
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systemically applied humanized monoclonal antibodies directed
against ToxA and ToxB, reducing the relapse rate from 25% to 7%
of patients19. Comparable reagents for the binary toxin are still
missing.
Camelids have evolved antibodies composed only of heavy
chains20. The antigen binding paratope of these antibodies is com-
posed of just one variable domain designated VHH21,22. VHHs pos-
sess an unusually long complementarity determining region 3
(CDR3) which can form finger-like extensions to penetrate into
and block the active site of an enzyme that is usually inaccessible
to conventional antibodies23,24. VHHs are easily cloned and
expressed as recombinant single domain antibodies, which exhibit
a high degree of chemical and thermal stability. Recombinant VHHs
are also known as nanobodies because of their dimensions in the
nanometer range (2 nm 3 3 nm)21,22. These nanobodies are highly
soluble, robust, and are easily converted into multivalent and/or
multispecific formats25. Asmonomers or chains of linkedmonomers,
nanobodies can neutralize their target antigens by binding only. In
these formats, nanobodies lack Fc-mediated effector functions, such
as complement activation or Fc-receptor mediated phagocytic clear-
ance. The latter, however, can easily be supplied by genetic fusion of
nanobodies to the Fc domains of conventional antibodies, thereby
converting nanobodies into a format resembling the original heavy
chain antibody21. Nanobodies have potential applications in various
disease areas, including infectious and inflammatory diseases21,22.
Hussack et al. recently reported the selection of nanobodies directed
against the repetitive receptor binding domains (RBD) of ToxA and
ToxB26. Some of the ToxA-specific nanobodies neutralized the cyto-
toxic activities of ToxA in cell culture models when added in 100–
1.000 fold molar excess. However, none of the ToxB-specific nano-
bodies was capable of neutralizing ToxB-mediated cytotoxicity in cell
culture models.
The goal of this study was to produce and characterize nanobodies
directed against the enzymatic and binding components of CDT.We
successfully selected several functional nanobodies against both of
these subunits from phage display libraries generated from immu-
nized llamas. Two of these nanobodies - one directed against CDTa
(l18), the other directed against CDTb (l-15.1g) - effectively blocked
cytotoxicity of the binary toxin at equimolar concentrations. These
nanobodies hold promise as new tools for research, diagnostic and
therapy of C. difficile associated disease.
Results
Llama immunizations and selection of CDT-specific nanobodies.
Three llamas were immunized with recombinant CDTa or CDTb
(Fig. 1). ELISA analyses confirmed a robust heavy chain antibody
response (Supplementary Fig. S1). VHH-Phage display libraries were
generated by PCR-amplification of the VHH-repertoire from blood
lymphocytes obtained 10–20 days after the last boost immunization
and cloning into the pHEN2 vector (Supplementary Table S1). CDT-
specific VHHs were selected by sequential panning of the phage
libraries on immobilized CDTa or CDTb. After each round of
selection, 24 clones were sequenced. The results revealed selection
of clones derived from several distinct VHH families (Table 1), with
CDR3 lengths ranging from 3 to 21 amino acid residues.
Production and reformatting of nanobodies. Recombinant nano-
bodies carrying a C-terminal chimeric His6x c-myc tag were
expressed as periplasmic secretory proteins in E. coli HB2151 cells.
SDS-PAGE analyses of periplasmic lysates obtained 3–4 h after
induction of transcription with IPTG usually revealed prominent
bands at 14–20 kDa corresponding to recombinant nanobodies
(Fig. 2). Nanobodies were readily purified from E. coli periplasmic
lysates by immobilized metal affinity chromatography (IMAC).
ELISA analyses with crude periplasmic lysates on immobilized CDTa
or CDTb using peroxidase-conjugated anti-c-myc antibodies confirmed
the specificity of five CDTa-selected nanobody families for CDTa
(Fig. 2) and of four CDTb-selected nanobody families for CDTb
(Supplementary Fig. S2). Note that production levels of nano-
bodies in the E. coli periplasm varied considerably, even among
members of the same nanobody family (Fig. 2). Moreover, nano-
bodies in periplasma lysates often yielded double bands in SDS-
PAGE analyses (Fig. 2, arrows). Only the upper band could be
Figure 1 | Immunization scheme of llamas with CDTa and CDTb.
(A) Schematic diagram of the toxin subunits used for immunization.
CDTa and CDTb are independently produced as secreted proteins with an
N-terminal signal peptide that is cleaved during secretion. CDTa consists
of two tandem ADP-ribosyltransferase (ART) domains. The N-terminal
ART domain does not possess enzymatic activity and mediates binding to
CDTb; the C-terminal ART domainmediates ADP-ribosylation of actin at
Arg 177 and contains a deepNAD1-binding cleft. Proteolytic cleavage of its
N-terminal activation domain (PA14) allowsCDTb to formoligomers that
bind CDTa and assists its delivery to the host cell cytosol. 3D models were
generated with PyMol using coordinates of the pdb file 2wn7 for CDTa
with NAD1 (cyan). CDTb wasmodeled onto the 3D structure of iota toxin
(pdb code 2j42) using SwissModel and assembled into the multimer by
alignment with anthrax toxin (pdb code 3hvd) using PyMol. (B) Three
llamas (Lama glama) were immunized subcutaneously with purified
recombinant CDTa or CDTb emulsified with Specol adjuvant, boosted
and bled as indicated in the time scale.
www.nature.com/scientificreports
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detected with c-myc-specific antibodies inWestern blot analyses and
only the upper band could be purified by IMAC (not shown),
indicating that the lower band lacked the C-terminal tags, most
likely as a consequence of proteolytic cleavage. Further, nano-
bodies purified from E. coli periplasm still contained substantial
levels of endotoxin (lipopolysaccharide), a potential concern for
use of nanobodies in subsequent cellular assays.
In order to avoid these problems of inconsistent production levels,
proteolytic degradation of C-terminal tags, and contamination by
endotoxin, we subcloned the nanobody coding region into a eucar-
yotic expression vector (pCSE2.5) that had been optimized for secret-
ory protein production in suspension cultures of HEK-6E cells in
serum free medium27,28. SDS-PAGE analyses of crude HEK cell cul-
ture supernatants harvested 6 d after transfection, indeed, revealed
consistently high yield production levels of nanobodies in both,
monovalent and bivalent formats (Fig. 3). Qualitative comparisons
of nanobody affinities were performed by ELISA using serial dilu-
tions of nanobodies. The results revealed nanobody affinities for
CDTa (Fig. 3) and CDTb (Supplementary Fig. S3) ranging from
0.5 nM to 15 nM, i.e. affinities comparable to those reported for
nanobodies selected from immunized llamas for other target
antigens21,24,29.
Mapping of binding epitopes. In order to assess whether the
selected nanobodies recognize overlapping or distinct epitopes on
CDTa or CDTb, binding analyses were performed in the presence of
Table 1 | Characteristics of CDTa-specific and CDTb-specific families of nanobodies
specificity llama family isolates variants CDR3 affinity (Kd) epitope IC50 tox IC50 ART
CDTa 6 l18 2 1 ECGGYGAH 1 nM 1 2 nM 2 nM
6 l-14 2 1 TYRPNTFTPAEYDY 1.5 nM 2 . 1 mM 4 nM
6 l-15 4 2 GGFTEAYSGTYYPDS 1.5 nM 3 . 1 mM 4 nM
6 l118 8 5 GGSGYGCYAFTPAYGMDY 1.5 nM 2,3 50 nM 4 nM
5037 s-21 18 4 ADQRVGYIEYYSGSSGKEYDY 3 nM 2,3 50 nM 4 nM
CDTb 180 l-3 13 9 RGY . 50 nM 1 . 1 mM -
180 l-15.1 13 10 KVGANILTRSIGYKY 0.5 nM 1 4 nM -
180 l-15.3 1 1 TNKBYTDGRLEEYDY 9 nM 2 . 1 mM -
180 l-19 1 1 DGRSNLRANYDSADYGMAY 15 nM 3 . 1 mM -
Family names indicate the presence of a short (s) or long hinge (l), the absence (-) or presence (1) of a disulfide bond connecting CDR2 and CDR3, and the length of the CDR3 in numbers of amino acid
residues. Isolates indicates the number of clones selected per family, variants indicates the number of clones carrying distinct but evidently related amino acid sequences. Variant amino acid positions in the
CDR3 are indicated in red. Epitopes are numbered arbitrarily (nanobodies that block the binding of one another are considered to recognize the same or overlapping epitopes). ‘‘IC50 tox’’ indicates the
nanobody concentration required to inhibit 50% rounding of HT29 cells upon incubation with 2 nM CDTa1b for 4 h at 37uC. ‘‘IC50 ART’’ indicates the nanobody concentration required to inhibit ADP-
ribosylation of actin by 2 nM CDTa by 50%.
Figure 2 | Production of monovalent nanobodies in the E. coli periplasm and verification of binding specificities. E. coli HB2151 cells were
transformedwith individual VHH-encoding pHEN2 vectors and protein expression was induced with IPTG for 3 h. Periplasmic lysates were prepared by
osmotic shock, clarified by centrifugation, and analyzed by SDS-PAGE and Coomassie staining (bottom). Binding specificity was analyzed by ELISA
using CDTa or BSA as a control protein (top). Representative results are shown for three families of CDTa-specific nanobodies. Results for CDTb-specific
families are shown in Supplementary Fig. S2. Family names indicate the presence of a long or short hinge, the absence or presence of an additional cysteine
pair in CDRs 2 and 3, and the number of amino acid residues in the CDR3 (see Table I). Family members with distinct amino acid sequences were
designated a, b, c, d etc. in order of decreasing number of isolates. Numbers on the bottom indicate the number of different amino acids between two
family members. Nanobodies marked by a circle were selected for subcloning into a eucaryotic expression vector.
www.nature.com/scientificreports
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excess unlabeled nanobodies carrying an epitope tag distinct from
that used for detection of the binding nanobody (Fig. 4). The results
permit grouping of nanobodies according to their relative epitope
specificities (Table 1). Nanobody l18 bound CDTa independently of
the other four nanobodies, while the latter showed partially over-
lapping epitopes: l118 blocked binding of l-14 and s-21, but did not
block binding of l-15; whereas s-21 blocked binding of l118 and l-15,
but not l-14. Nanobodies l-15.3 and l-19 boundCDTb independently
of each other and of the other two nanobodies. Nanobody families l-3
and l-15.3 blocked one another. In case of CDTa, for which a 3D-
structure is available (pdb code 2wn7), molecular modeling analyses
yielded plausible binding modes for nanobodies l18, l-14, and l118
at the active site of CDTa (Supplementary Fig. S4).
Five of five CDTa-specific nanobodies inhibit the enzymatic acti-
vity of CDTa. In order to assess whether the CDTa-selected nano-
bodies can interfere with the enzymatic activity of CDTa, we
analyzed CDTa-catalyzed ADP-ribosylation of actin in HEK cell
lysates in the presence of excess nanobodies (Fig. 5). The results
show that all five CDTa-specific nanobody families completely
blocked ADP-ribosylation of actin catalyzed by CDTa. Titration
analyses indicate that the most potent nanobodies l18, l-14 and
l118e blocked ADP-ribosylation at equimolar ratios with CDTa.
CDTa-specific nanobody l18 and CDTb-specific nanobody l-
15.1g effectively inhibit CDT-induced cytotoxicity. Treatment of
cells expressing LSR, the CDT receptor, with a mixture of
recombinant CDTa and CDTb results in profound cytotoxicity as
evidenced by rounding and detachment of cells18 (Supplementary
Fig. S5). In order to assess whether any of the selected nanobodies
can interfere with CDT-mediated cytotoxicity, we assessed the
integrity of HT29 cells by microscopy following incubation with
CDTa 1 CDTb for 4 h at 37uC in the absence or presence of
nanobodies in 16 fold molar excess (Fig. 6). Cells were fixed and
counterstained with fluorescently labeled Phalloidin which binds
to filamentous actin, but not to monomeric actin. The results show
that the CDTa-specific nanobody l18 and CDTb-specific nanobody
l-15.1g effectively protected HT29 cells from the cytotoxic effects of
CDTa1CDTb, nanobodies l-15.1b, l118b and s-21a showed partial
protection, and the other nanobodies did not show any detectable
effect on CDTa1b mediated disruption of filamentous actin (Fig. 6).
Titration analyses revealed effective neutralization by l18 and by
Figure 3 | Production of reformatted nanobodies in transfected HEK-6E cells and comparative analyses of binding affinities. HEK-6E cells were
transfected with cDNA-expression constructs encoding nanobodies fused C-terminally to chimeric tags (c-myc-His6x or avi-His6x) or to the Fc domain
of mouse IgG2c (mFc). Transfected cells were cultured in serum free medium for 6 d. Cell supernatants were clarified by centrifugation and analyzed by
SDS-PAGE and Coomassie staining (top). Qualitative comparison of nanobody affinities was performed by ELISA using serial dilutions of monovalent
nanobodies and wells coated with CDTa. After 20 minutes of incubation, wells were washed three times to remove unbound proteins and bound
nanobodies were detected with a peroxidase-conjugated monoclonal antibody directed against the c-myc tag. A c-myc tagged nanobody directed against
ARTC229 was used as negative control. Symbols used for the respective nanobodies and the calculated dissociation constants are indicated in the middle.
Representative results are shown for five families of CDTa-specific nanobodies. Results for CDTb-specific families are shown in Supplementary Fig. S3.
www.nature.com/scientificreports
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Figure 4 | Mapping of the epitope specificity of nanobodies by cross-blocking analyses. For analysis of epitope specificities, selected nanobodies were
subjected to competitive binding analyses (A). Antigens were immobilized on 96-well plates and pre-incubated with nanobody-Fc fusion proteins (2 mg/
well) for 60 min at RT before addition of c-myc tagged nanobodies precomplexed with a peroxidase-conjugated anti-c-mycmAb (50 ng nanobody/well).
The schematic diagram illustrates the experimental set-up, PO: peroxidase. (B) Schematic diagrams illustrating the relative localization of the binding
epitopes of the analyzed nanobodies.
www.nature.com/scientificreports
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l-15.1g at equimolar concentrations with CDTa1b, while neutraliza-
tion with l118b and l-15.1b required higher concentrations of
nanobodies (Supplementary Fig. S6). The results of radio-ADP-
ribosylation analyses confirm that nanobodies l18, l118b and
l-15.1g effectively prevent and that nanobody l-15.1b partially
prevents ADP-ribosylation of actin in response to treatment of
HT29 cells with CDTa1b (Supplementary Fig. S7).
CDTa-specific nanobody l18 inhibits CDT-induced disruption of
transepithelial resistance. The transepithelial electrical resistance
(TEER) is a sensitive measure of the integrity of a monolayer of
epithelial cells. Disruption of the cell cytoskeleton can be detected
by a loss of TEER. In order to assess whether the CDTa-specific
nanobody l18 could also inhibit CDTa1b induced breakdown of
TEER, we measured TEER in established monolayers of MDCK C7
cells incubated with CDTa 1 CDTb in the presence of l18 or a
control nanobody. The results show that l18 effectively inhibits
CDTa-induced loss of TEER (Supplementary Fig. S8).
Discussion
The goal of this study was to produce functional nanobodies directed
against the enzymatic and binding components of CDT.We success-
fully selected several functional nanobodies against both of these
subunits from phage display libraries generated from immunized
llamas.
It has been reported that nanobodies derived from immunized
llamas display a propensity to bind crevices on protein surfaces,
e.g. the active site crevice of enzymes23,24. In most cases reported to
date where llamas have been immunized with an enzyme, a substan-
tial fraction of the selected nanobodies functionally block the enzym-
atic activity of their target21. Our results with the CDTa-selected
nanobodies are in accord with these previous reports.
Co-crystallization studies have revealed that the exceptionally
long CDR3 of nanobodies can form finger-like protrusions that
extend into and block the active site24,30. The crystal structure of
CDTa, indeed, contains a deep NAD1-binding pocket31. It is, thus,
conceivable that some of the CDTa-specific nanobodies reported
here extend their CDR3 (containing 8, 14, 15, 18 and 21 amino acid
residues, Table 1) into the deep NAD1-binding cleft of CDTa.
Although co-crystal structures of actin in complex with CDTa are
not yet available, the 3D structure of actin in complex with the
enzymatic component of the related iota toxin of C. perfringens
revealed an extended contact area between actin and iota toxin adja-
cent to the NAD1-binding crevice32. It is, thus, also possible that
some of the selected nanobodies sterically block ADP-ribosylation
of actin without directly blocking the NAD1-binding site. Molecular
modeling analyses for the binding epitopes of nanobodies l18, l-14,
and l118, indeed yielded plausible binding sites consistent with the
experimental data (Supplementary Fig. S4). The predicted binding
sites indicate that these three nanobodies interfere with both, binding
of NAD1 and actin. These models can be evaluated by site-directed
mutagenesis of CDTa, and ultimately, by co-crystallization of the
nanobodies and CDTa.
Blocking the binding of a toxin to its host cell receptor is generally
considered the most suitable strategy to neutralize toxins with anti-
bodies or nanobodies17,26. Hussack et al. recently generated nanobo-
dies directed against the receptor binding domain ofC. difficile ToxA
and ToxB, each of which are composed of multiple repetitive car-
bohydrate binding domains at their C-termini26. When added in
3000 fold molar excess, six of seven selected nanobodies inhibited
the cytotoxicity of ToxA whereas none of seven selected nanobodies
could block the cytotoxicity of ToxB. Neutralization of ToxA at lower
nanobody concentrations was enhanced significantly when nanobo-
dies recognizing independent epitopes of ToxAwhere added in com-
bination rather than individually. In our study, we observed effective
neutralization of CDTa1b for two of our nanobodies (l18 and
l-15.1g) even at equimolar concentrations (Supplementary Fig. S6).
The more effective neutralization of our nanobodies may reflect
structural differences of the binary toxin and the large cytotoxins33.
While the receptor binding domain of the large holotoxins contains
multiple repetitive lectin-like carbohydrate-bindingmodules, CDTb,
in contrast, does not contain any repetitive binding modules and
presumably binds its receptor LSR via a unique site18. CDTb is
thought to form heptamers that are stabilized by binding to LSR34.
The CDTb-specific nanobody thus could neutralize the cytotoxicity
either by steric interference with the assembly of CDTb into hepta-
mers or by interfering with binding of CDTb to CDTa or to LSR. In
either case, high affinity binding of a nanobody might be effective
even at equimolar concentrations.
Surprisingly, three of five nanobodies selected for binding to
CDTa also neutralized cytotoxicity of the binary toxin (Fig. 6). All
of these nanobodies also effectively blocked ADP-ribosylation of
actin catalyzed by monomeric CDTa (Fig. 5). Interaction of CDTa
with CDTb is thought to be mediated via the N-terminal
pseudo-ART domain, while the C-terminal ART domain catalyzes
ADP-ribosylation of actin31. Since all five nanobodies block ADP-
ribosylation of actin, it is unlikely that these nanobodies sterically
interfere with binding of CDTa to CDTb. Rather, it is more likely that
these nanobodies bind to the catalytic domain and then interfere
with translocation of CDTa to the cytosol.
Although the precise translocationmechanism is not yet known, it
is thought to require unfolding of the enzymatic domain, transloca-
tion of the unfolded polypeptide chain through a narrow channel and
subsequent refolding of the translocated chain into an active enzyme
in the cytosol35,36. Nanobodies contain a canonical disulfide bond
connecting the two ß-chains of the immunoglobulin domain21.
Similar to some other llama derived nanobodies, CDTa-specific
nanobody l18 contains an additional pair of cysteine residues that
likely form a disulfide bridge connecting the CDR1 and CDR3. Co-
translocation of the nanobody to the cytosol, presumably would
require unfolding and reduction of these disulfide bonds. Forced
expression of nanobodies in the cytosol has been achieved in numer-
ous cases21,22. Indeed, fusion of nanobodies directed against cytosolic
or nuclear target proteins to fluorescent proteins indicate that nano-
bodies fold correctly in the reducing environment of the cytosol and
bind their target with high specificity and affinity37,38.
In this context it is important to note that nanobodies directed
against the receptor binding domain of a toxin, in general would be
ineffective once the cytotoxic enzymatic domain has entered the cell
Figure 5 | CDTa-specific nanobodies inhibit the enzymatic activity of
CDTa. HEK cells were lysed with Triton-X-100 and cell lysates were
clarified by centrifugation. Before addition to the lysates, CDTa was
preincubated for 20 min with serial dilutions of CDTa-specific or control
(co) nanobodies at the indicated molar ratios of VHH:CDTa. 32P-NAD1
was added as a substrate for CDTa-catalyzed ADP-ribosylation of actin.
Reactions were stopped after 15 min by addition of SDS-PAGE sample
buffer. Proteins were size fractionated by SDS-PAGE and covalently
incorporated radioactivity was detected by exposing the dried gel to an X-
ray film.
www.nature.com/scientificreports
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and dissociated from the receptor binding domain. In contrast,
nanobodies directed against the enzymatic domain could still neut-
ralize cytotoxicity after entry, provided that the nanobodies either are
expressed by the cell itself or are efficiently translocated to the cytosol
as effectively as the enzymatic component39.
Expression by the host cell could be achieved by delivery of nano-
body-encoding cDNA either by transfection or infectionwith recom-
binant viruses40,41. Translocation to the cytosol could be achieved by
fusion to translocation domains, e.g. the pseudo-ART domain of
CDTa42 or by cationic transfection polymers43.
Figure 6 | CDTa-specific nanobody l18 and CDTb-specific nanobody l-15.1g inhibit CDTa1b induced cytotoxicity. Before addition to cultures of
adherent HT29 cells, CDTa and CDTb were preincubated with a 16 fold excess of CDTa- or CDTb-specific nanobodies. Four hours after addition of
toxins, cells were fixed and cellular morphology was assessed by differential interference microscopy. The cellular cytoskeleton was stained with
the F-actin-staining dye phalloidin-rhodamine, cell nuclei were stainedwith theDNA staining dyeHoechst 33342. Apotome-images were captured with a
Zeiss Axiovert 200M microscope. Control cells (top) were incubated for four hours in the absence or presence of CDTa1b.
www.nature.com/scientificreports
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The role of the binary CDT toxin for pathogenicity of C. difficile
strains is still a controversial issue12,34,44. Many of the clinically most
aggressive strains ofC. difficile express the binary toxin in addition to
one or both of the large cytotoxins ToxA and ToxB45. Moreover,
recent studies suggest that CDT may increase pathogenicity by
enhancing adherence of bacteria to epithelial cells that form
CDTa-induced protrusions14,15. Another study showed a high cor-
relation between detections of the CDTa gene and a high recurrence
rate of C. difficile colitis46. However, good diagnostic tools to assess
the presence of CDT in stool samples are still lacking. The nanobo-
dies described here provide a promising basis for the development of
more sensitive diagnostic tools, e.g. by use of immobilized nanobo-
dies to enrich toxins from stool samples or culture supernatants.
These nanobodies may also provide useful experimental tools to
assess the relative role of CDTa vs. the two large glucosylating cyto-
toxins in experimental models of CDAD.
The standard therapy for C. difficile infection is treatment with
metronidazole, vancomycin, or fidaxomicin. 90% of all treated
patients respond to this therapy, but of these patients 15–30% suffer
from relapsing infection3,6,47. Therefore, there is a need for the
development of alternative therapeutic options to treat C. difficile
infections48. Recent studies have provided promising results for two
different treatment strategies: systemic treatment with toxin-neutral-
izing antibodies and fecal microbiome transplantation19,49,50. The
nanobodies reported here may provide a complementary approach.
A recent clinical study revealed the therapeutic potential of passive
immunotherapy with neutralizing antibodies19: 101 patients received
a single infusion of a ToxA-neutralizing monoclonal antibody in
combination with a ToxB-neutralizing monoclonal antibody. This
reduced the recurrence rate to 7% in the antibody group vs. 25% in
the placebo group19. Similarly, the systemic administration of the
neutralizing CDT-specific nanobodies described here may have
therapeutic benefit. In comparison to conventional monoclonal anti-
bodies, nanobodies provide several advantages, including a lower
cost of production and more effective tissue penetration21,22. As
monomers or dimers, however, nanobodies have a short half life
and are rapidly eliminated from circulation by renal filtration. Two
strategies have been applied successfully to increase the in vivo half
life of nanobodies: 1) genetic fusion to an albumin-specific nanobody
and 2) genetic fusion to the Fc domain of a conventional IgG anti-
body21,25. Both strategies utilize the recycling function of the neonatal
Fc receptor which binds independently to albumin and to IgG anti-
bodies, protecting both from intracellular degradation51. Fusion to
the Fc domain also reconstitutes the phagocytic clearance of the Ag-
Ab complexes via Fcc-receptors52. Thus, the modular nature of
nanobodies allows tailoring of nanobodies to specific needs, e.g. by
fusion to other nanobodies or to the Fc-domains of conventional
antibodies.
For therapeutic purposes, nanobodies can, in principle, be
administered systemically and locally. In recent clinical trials,
llama-derived nanobodies have been administered systemically by
intravenous or subcutaneous injections to more than 700 humans,
without any adverse side effects53. Nanobodies could also be admi-
nistered topically to the gastrointestinal tract, e.g. by oral or rectal
administration. Application via the oral route may require encap-
sulation to avoid excessive damage to nanobodies by low gastric pH
and pancreatic proteases. Various encapsulation strategies have been
established for the oral administration of therapeutic proteins43,54.
Moreover, using site directed mutagenesis it has been possible to
select nanobodies resistant to low pH and pancreatic proteases55.
Expression of nanobodies as cell surface or secretory proteins by
lactobaccili is another feasible option56,57. Finally, rectal administra-
tion, e.g. as a supplement to fecal microbiome transplantation, may
also be possible50. To this end, immobilization of nanobodies on
beads may aid absorption and rectal elimination of soluble toxins
from the gastrointestinal tract.
In conclusion, the nanobodies described here provide a promising
basis for the development of more efficient diagnostic and therapeu-
tics tools for C. difficile mediated diseases.
Methods
Protein production and llama immunizations. The enzymatic (CDTa) and binding
components (CDTb) of CDT (Fig. 1) were produced separately in E. coli or B.
megaterium and were purified as previously described14,15. The binding component
was activated by treatment with trypsin58. Three llamas (Lama glama) were
immunized subcutaneously with purified recombinant proteins emulsified with
Specol adjuvant29,39,59. The humoral immune response was monitored in serially
diluted serum by ELISA on microtiter plates (Nunc MaxiSorp, Thermo Fisher
Scientific, Waltham, MA) coated with recombinant CDTa or CDTb (100 ng/well).
Bound antibodies were detected using mouse monoclonal antibodies directed against
llama IgG2 (clone 198D) and IgG3 (clone 8E1) kindly provided by Dr. Judith
Appelton, Cornell University, NY60 and peroxidase-conjugated goat anti-mouse IgG
(GE Healthcare, Chalfont St Giles, UK). Animals were bled 10–14 d after the 3rd or
4th boost.
Construction of phage display libraries and selection of CDT-specific VHHs.
Mononuclear cells were isolated from 120 ml of blood by Ficoll-PaqueTM (GE
Healthcare, Chalfont St Giles, UK) gradient centrifugation. RNA purified from these
cells by TRIZOL reagent (Invitrogen, Carlsbad, CA) was subjected to cDNA synthesis
with random hexamer primers. The VHH coding region was amplified by PCR with
degenerate VHH-specific primers SHFmu: tcgcggccca gccggccatg gcgcaggtsm
arctgcagga gtcwgg, SHRmu: atggtgatga tgattgtgcg gccgcgctgg ggtcttcgct gtggtgcg,
LHFmu: tcgcggccca gccggccatg gccgatgtgc agctgcaggm gtcwggrgga gg, LHRmu:
atggtgatga tgatgtgcgg ccgctggttg tggttttggt gtcttggg. PCR products were purified from
agarose gels, digested sequentially with SfiI and NotI (NEB, Ipswich, MA) and cloned
into the pHEN2 phagemid vector downstream of the PelB-leader peptide and
upstream of the chimeric His6x-Myc epitope tag39,61. Transformation into XL1-Blue
E. coli (Stratagene, La Jolla, CA) yielded libraries with sizes of 4.0 3 105–107 clones.
Phage particles were precipitated with polyethylene glycol from culture supernatants
of transformants infected with a 10-fold excess of M13K07 helper phage (GE
Healthcare, Chalfont St Giles, UK). Panning of specific phage was performed using
either toxins immobilized on microtiter plates (Nunc MaxiSorp, Thermo Fisher
Scientific, Waltham, MA) or in solution with biotinylated toxins and subsequent
capture on streptavidin-coated magnetic beads (Life Technologies, Carlsbad, CA).
Phage particles (1.63 1014) incubated with toxins for 60 min with agitation at room
temperature in PBS, 10% Carnation non fat dry milk powder (Nestle´, Glendale, CA).
Following extensive washing, bound phages were eluted with 50 mM diethylamine
and neutralized with 1MTris-HCl pH 8. Eluted phages were titrated and subjected to
two more rounds of panning, following the same procedure. Phage titers were
determined at all steps by infection of TG1 E. coli cells (Stratagene, La Jolla, CA).
Plasmid DNA was isolated from single colonies and subjected to sequence analyses
using pHEN2-specific forward and reverse primers.
Production of recombinant proteins and reformatting of nanobodies.Monomeric
nanobodies were expressed in HB2151 E. coli cells (GE Healthcare, Chalfont St Giles,
UK). Protein expression was induced with IPTG (Roche, Rotkreuz, Switzerland)
when bacterial cultures had reached an OD600 of 0.5 and cells were harvested after
further cultivation for 3–4 h at 37uC. Periplasmic lysates were generated by osmotic
shock and removal of bacterial debris by high speed centrifugation. The coding region
of selected nanobodies was subcloned using NcoI and NotI into the pCSE2.5 vector27
(kindly provided by Thomas Schirrmann, Braunschweig) so as to fuse C-terminal
tags, including His6x-c-myc, avi-His6x, or the CH2 and CH3 domains of mouse
IgG2c. Monomeric nanobodies and nanobody-Fc fusion proteins were expressed in
transiently transfected HEK-6E cells. Six days post transfection, supernatants were
harvested and cleared by centrifugation. Nanobodies were purified by immobilized
metal affinity chromatography using Ni-NTA agarose (Sigma, St Louis, MO),
nanobody-Fc fusion proteins were purified by affinity chromatography on protein G-
sepharose (GE-Healthcare, Chalfont St Giles, UK).
ELISA. CDTa or CDTb (100 ng/100 ml PBS/well) were adsorbed to 96-well Nunc
MaxiSorp plates (Thermo Fisher Scientific, Waltham, MA) at 4uC over night. Wells
were washed twice with PBS and blocked for 2 hours with PBS containing 5% nonfat
powdered milk at room temperature. Wells were incubated for 30 min with
nanobody-containing periplasma lysates (diluted 1510 in PBS). Following washing
with PBS/0.05% Tween 20, bound nanobodies were detected with peroxidase-
conjugated anti-c-Myc mAb 9E10 (Sigma, St Louis, MO).
Alternatively, wells were incubated with HEK-cell supernatants containing VHH-
Fc fusion proteins and bound antibodies were detected with peroxidase conjugated
anti-mouse IgG (GE Healthcare, Chalfont St Giles, UK). In some experiments
monovalent nanobodies (10 ng) were dimerized by preincubation for 30 min with
peroxidase-conjugated anti-c-Myc mAb 9E10 (200 ng). Bound peroxidase was
visualized using 3,3’9,5,5’9-Tetramethylbenzidine (TMB) (Sigma, St Louis, MO) as
substrate. For affinity analyses, wells were incubated for 60 min with serial dilutions
of monovalent nanobodies in PBS containing 10 mg/ml BSA. Wells were washed
three times with PBS/0.05% Tween 20. Bound antibodies were detected with perox-
idase-conjugated anti-c-Myc mAb 9E10 and TMB as substrate. For epitope analyses,
wells were preincubated with excess monovalent nanobodies or nanobody-Fc fusion
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proteins (500 ng/100 ml PBS, 1% BSA) for 30 min at RT before addition of precon-
jugatedVHH-anti-c-myc and further incubation for 20 min at RT. The absorbance at
450 nmwas measured using a Victor3 ELISA-reader (Perkin-Elmer, Waltham,MA).
ADP-ribosylation assays. To monitor ADP-ribosylation of actin, HEK cells were
lysed for 30 min at 4uC in PBS containing 0.5% Triton-X-100 (107 cells/ml) and cell
lysates were clarified by high speed centrifugation (15 min 13.000 g). CDTa (0.2 mM)
was preincubated with serial dilutions of nanobodies (2 mM–0.12 mM) in PBS
containing 10 mg/ml BSA for 20 min at RT. HEK cell lysates (50 ml) were incubated
with toxin/nanobody (50 ml) in the presence 32P-NAD1 for 10 minutes at 37uC. The
reaction was stopped by addition of SDS-PAGE sample buffer (NuPAGEH,
Invitrogen, Carlsbad, CA). Proteins were size-fractionated on precast NuPAGEH gels
by SDS-PAGE and stained with Coomassie Blue (Invitrogen, Carlsbad, CA).
Radiolabeled proteins were detected by autoradiography for 15 h at280uC using X-
ray film (GE Healthcare, Chalfont St Giles, UK).
Cytotoxicity assays. Cytotoxicity assays were carried out by microscopic analyses of
the cellular morphology of subconfluent HT29 human colon carcinoma cells grown
on glass-bottom 96 well microtiter plates (ibidi, Martinsried, Germany). CDTa
(2.4 ng/100 ml) and protease activated CDTb (5 ng/100 ml) were preincubated for
30 min at 37uC with serial dilutions of nanobodies before addition to HT29 cells.
Cells were incubated for 4 h at 37uC, gently washed, and fixed in 4%
paraformaldehyde. Fixed cells were counterstained with rhodamine-phalloidin and
Hoechst 33342 (Molecular Probes, Life Technologies, Carlsbad, CA), and analyzed by
microscopy with a Zeiss Axiovert 200M microscope equipped with digital
interference contrast and an apotome (Zeiss, Oberkochen, Germany).
Additional cytotoxicity assays were carried out by monitoring the transepithelial
resistance (TEER) of confluent monolayers of MDCK C7 cells62 grown on 0.4 mM
filter-plates with a Volt Ohm meter (Merck Millipore, Billerica, MA, USA). Before
addition to the culture medium, CDTa (10 nM) and CDTb (20 nM) were preincu-
bated with excess nanobodies (200 nM) for 30 min at 37uC. TEER values were
determined every hour (n53) and background values (medium alone) were
substracted.
Molecular modeling.Molecular modeling of the binding epitopes of three VHHs to
CDTa (pdb code 2wn7) were performed using BioLuminate (version 1.7,
Schrodinger, New York, NY)63. Homology models were built with the antibody
prediction module in BioLuminate using framework templates obtained from the
curated antibody database. CDR loops were grafted from the database based on a
combination of structure clustering, sequence similarity and stem residue geometry
matching. BioLuminate automatically preserved the extra disulfide bond in
nanobodies l18 and l118 that connects CDR2 andCDR3 if the template also had one
in the aligned position. In other cases, the formation of the disulfide bond was forced
manually before de novo loop prediction. Four models were built for l18, six models
for l-14, and five models for l118. All of these models were used for docking to CDTa
using Piper64. Prior to docking, NAD1 was removed from CDTa using the Protein
PreparationWizard65. An attractive potential (scaling the vdW attractive term by 1.1)
was applied to the NAD1-binding site, which helped to restrain the sampling to this
site. 70000 rotations were sampled and the top 30 poses were returned from each
docking job. The following criteria were used to prune the docking poses: (a) docking
poses with low surface complementarity (,0.3) were discarded; (b) VHHs binding
with non-CDR regions were discarded; (c) l-14 and l118 bind partially overlapping
epitopes; (d) l18 does not block or is not blocked by l-14 or l118; (e) all VHHs block
binding of NAD1 and/or actin. The most plausible docking poses that passed the
above criteria were: the #16 pose from the 2nd homology model of l18, the #4 pose
from the 1st homology model of l-14, and the #1 pose from the 2nd homology model
of l118 (Supplementary Figure S4). The templates used for building these models
were: (1) l18: framework – 4JVP, CDR1 - 4KDT, CDR2 – 4JVP, CDR3 – 1MAM; (2)
l-14: framework – 3STB, CDR1 – 3VG9, CDR2 – 2XA3, CDR3 – 2AJ3; (3) l118:
framework – 3STB, CDR1 – 1NFD, CDR2 – 4NBZ, CDR3 – de novo.
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